Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.53 - $22.19
Previous CloseN/A
Volume14.25K
Average Volume (3M)259.39K
Market Cap
$389.86M
Enterprise Value$471.18M
Total Cash (Recent Filing)$15.94M
Total Debt (Recent Filing)$25.61K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 07, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.61
Shares Outstanding37,129,555
10 Day Avg. Volume201,550
30 Day Avg. Volume259,395
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.30K
Enterprise Value/Ebitda-5.51
Forecast
1Y Price Target
$31.00Price Target Upside185.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Celcuity News
PremiumCompany Announcements
Celcuity Inc. Reports Q3 Progress and Financials
---
Bulls Say, Bears Say
Bulls Say
Financial GuidanceThe company ended with $264.1 million in cash and expects a financial runway through 2026.
Study ResultsThere is an opportunity for upside from the upcoming VIKTORIA-1 study results.
Trial EnrollmentThe PIK3CA WT cohort in the VIKTORIA-1 trial is fully enrolled, and Celcuity expects to report data from these patients during late Q1 or Q2 2025.
Bears Say
Revenue And EarningsThe company reported no revenues, and a net loss of $0.70 per diluted share, compared to consensus estimate of no revenues and a net loss of $0.65 per diluted share.
Study DelaysThe readout for the highly anticipated PIK3CA WT cohort in the Phase 3 VIKTORIA-1 trial in 2L HR +/HER2- advanced breast cancer has been delayed.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $8.53 and its highest was $22.19 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $389.86M.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Nov 14, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.653 by -$0.047.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -0.71.
How many shares outstanding does Celcuity have?
Celcuity has 37,129,555 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.653. Following the earnings report the stock price went down -10.276%.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
---
Celcuity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (185.98% Upside)
$31.00 (185.98% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 803.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.40%
12-Months-Change
Fundamentals
Return on Equity
-77.47%
Trailing 12-Months
Asset Growth
91.76%
Trailing 12-Months
Company Description
Celcuity
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
---
CELC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated Celcuity's strong progress in its clinical trials and financial positioning, with significant milestones achieved for gedatolisib's development. Despite a higher net loss and operating cash use, the company maintains a robust cash position and anticipates substantial future revenue opportunities. The market feedback and safety profile of gedatolisib are promising, although trial event rates remain a challenge.Read More>---
CELC Stock 12 Month Forecast
Average Price Target
$31.00
▲(185.98% Upside)
Technical Analysis
Best Analysts Covering CELC
1 Year
---